Connor Clark & Lunn Investment Management Ltd. Takes $9.70 Million Position in Revvity Inc. $RVTY

Connor Clark & Lunn Investment Management Ltd. acquired a new position in Revvity Inc. (NYSE:RVTY) in the 2nd quarter, according to its most recent 13F filing with the Securities and Exchange Commission. The institutional investor acquired 87,145 shares of the company’s stock, valued at approximately $9,696,000.

Other institutional investors also recently bought and sold shares of the company. CYBER HORNET ETFs LLC bought a new stake in Revvity during the second quarter valued at about $32,000. Ascentis Independent Advisors purchased a new stake in Revvity in the first quarter worth about $29,000. MUFG Securities EMEA plc purchased a new stake in Revvity in the second quarter worth about $34,000. Global Retirement Partners LLC bought a new position in shares of Revvity in the second quarter worth about $51,000. Finally, Headlands Technologies LLC bought a new position in shares of Revvity in the second quarter worth about $49,000. 86.65% of the stock is owned by institutional investors.

Revvity Price Performance

Shares of Revvity stock opened at $126.31 on Thursday. The stock’s 50-day simple moving average is $112.94 and its 200-day simple moving average is $100.82. Revvity Inc. has a 52 week low of $81.22 and a 52 week high of $126.90. The company has a market capitalization of $14.09 billion, a price-to-earnings ratio of 60.15, a PEG ratio of 2.27 and a beta of 1.07. The company has a quick ratio of 1.50, a current ratio of 1.80 and a debt-to-equity ratio of 0.36.

Revvity (NYSE:RVTY) last released its quarterly earnings data on Tuesday, August 4th. The company reported $1.41 earnings per share for the quarter, topping analysts’ consensus estimates of $1.21 by $0.20. Revvity had a return on equity of 8.34% and a net margin of 8.16%.The firm had revenue of $729.69 million during the quarter, compared to analyst estimates of $702.96 million. During the same quarter in the prior year, the company posted $1.18 earnings per share. The business’s quarterly revenue was down 1.3% compared to the same quarter last year. Revvity has set its FY 2026 guidance at 5.300-5.400 EPS. As a group, analysts expect that Revvity Inc. will post 5.36 earnings per share for the current fiscal year.

Revvity Dividend Announcement

The firm also recently declared a quarterly dividend, which will be paid on Friday, November 13th. Shareholders of record on Friday, October 23rd will be paid a $0.07 dividend. This represents a $0.28 annualized dividend and a yield of 0.2%. The ex-dividend date is Friday, October 23rd. Revvity’s dividend payout ratio is presently 13.33%.

Analyst Upgrades and Downgrades

A number of brokerages recently issued reports on RVTY. JPMorgan Chase & Co. cut their price objective on Revvity from $96.00 to $90.00 and set a “neutral” rating for the company in a research note on Wednesday, May 6th. Weiss Ratings upgraded shares of Revvity from a “sell (d+)” rating to a “hold (c-)” rating in a research note on Thursday, July 30th. Wolfe Research started coverage on shares of Revvity in a report on Tuesday, June 2nd. They set a “peer perform” rating on the stock. Barclays lifted their price target on shares of Revvity from $95.00 to $105.00 and gave the company an “equal weight” rating in a report on Thursday, May 7th. Finally, TD Cowen reissued a “buy” rating on shares of Revvity in a research note on Wednesday, July 15th. Three analysts have rated the stock with a Buy rating and twelve have issued a Hold rating to the stock. According to data from MarketBeat.com, the company currently has a consensus rating of “Hold” and a consensus target price of $108.36.

Revvity Company Profile

Revvity, Inc is a global provider of technology-enabled solutions for the life sciences, diagnostics and applied markets. The company develops and supplies a range of products and services, including reagents and consumables, laboratory instruments, workflow automation, software analytics and technical support. Its portfolio supports applications in drug discovery, genomics, cell biology research, environmental and food safety testing, industrial quality control and clinical diagnostics.

Tracing its heritage to Perkin-Elmer, founded in 1937, Revvity began trading on the New York Stock Exchange under the ticker symbol RVTY in January 2024 following a corporate rebranding.